238 related articles for article (PubMed ID: 23762417)
1. Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma.
Wild AT; Gandhi N; Chettiar ST; Aziz K; Gajula RP; Williams RD; Kumar R; Taparra K; Zeng J; Cades JA; Velarde E; Menon S; Geschwind JF; Cosgrove D; Pawlik TM; Maitra A; Wong J; Hales RK; Torbenson MS; Herman JM; Tran PT
PLoS One; 2013; 8(6):e65726. PubMed ID: 23762417
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib modulates the radio sensitivity of hepatocellular carcinoma cells in vitro in a schedule-dependent manner.
Li Q; Hu Y; Xi M; He L; Zhao L; Liu M
BMC Cancer; 2012 Oct; 12():485. PubMed ID: 23088517
[TBL] [Abstract][Full Text] [Related]
3. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model.
Chen JC; Chuang HY; Hsu FT; Chen YC; Chien YC; Hwang JJ
Oncotarget; 2016 Dec; 7(51):85450-85463. PubMed ID: 27863427
[TBL] [Abstract][Full Text] [Related]
5. Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy.
Heo J; Breitbach CJ; Moon A; Kim CW; Patt R; Kim MK; Lee YK; Oh SY; Woo HY; Parato K; Rintoul J; Falls T; Hickman T; Rhee BG; Bell JC; Kirn DH; Hwang TH
Mol Ther; 2011 Jun; 19(6):1170-9. PubMed ID: 21427706
[TBL] [Abstract][Full Text] [Related]
6. A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo.
Xu YY; Chen L; Wang GL; Zhou JM; Zhang YX; Wei YZ; Zhu YY; Qin J
BMC Cancer; 2013 Nov; 13():527. PubMed ID: 24195809
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human acid sphingomyelinase as an adjuvant to sorafenib treatment of experimental liver cancer.
Savić R; He X; Fiel I; Schuchman EH
PLoS One; 2013; 8(5):e65620. PubMed ID: 23724146
[TBL] [Abstract][Full Text] [Related]
8. Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response.
Huang CY; Hsieh FS; Wang CY; Chen LJ; Chang SS; Tsai MH; Hung MH; Kuo CW; Shih CT; Chao TI; Chen KF
Eur J Cancer; 2018 Oct; 102():10-22. PubMed ID: 30103095
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
Lin HH; Feng WC; Lu LC; Shao YY; Hsu CH; Cheng AL
Cancer Lett; 2016 Oct; 381(1):58-66. PubMed ID: 27431312
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo.
Yu W; Gu K; Yu Z; Yuan D; He M; Ma N; Lai S; Zhao J; Ren Z; Zhang X; Shao C; Jiang GL
Cancer Lett; 2013 Feb; 329(1):109-17. PubMed ID: 23142289
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy of sorafenib with mesenchymal stem cells as a novel cancer treatment regimen in xenograft models of hepatocellular carcinoma.
Seyhoun I; Hajighasemlou S; Muhammadnejad S; Ai J; Nikbakht M; Alizadeh AA; Hosseinzadeh F; Mirmoghtadaei M; Seyhoun SM; Verdi J
J Cell Physiol; 2019 Jun; 234(6):9495-9503. PubMed ID: 30362607
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index.
Ohki T; Kondo M; Karasawa Y; Kawamura S; Maeshima S; Kojima K; Seki M; Toda N; Shioda Y; Tagawa K
Adv Ther; 2017 May; 34(5):1097-1108. PubMed ID: 28389996
[TBL] [Abstract][Full Text] [Related]
14. Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo.
Zhang W; Liu S; Liu K; Ji B; Wang Y; Liu Y
Oncol Rep; 2014 Nov; 32(5):1913-22. PubMed ID: 25176394
[TBL] [Abstract][Full Text] [Related]
15. A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib.
de la Torre MA; Buades-Mateu J; de la Rosa PA; Lué A; Bustamante FJ; Serrano MT; Testillano M; Lorente S; Arenas JI; Gil C; Iñarrairaegui M; Sangro B
Liver Int; 2016 Aug; 36(8):1206-12. PubMed ID: 26910784
[TBL] [Abstract][Full Text] [Related]
16. Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation.
Yan Y; Wang L; He J; Liu P; Lv X; Zhang Y; Xu X; Zhang L; Zhang Y
Biomed Pharmacother; 2017 Apr; 88():395-402. PubMed ID: 28122304
[TBL] [Abstract][Full Text] [Related]
17. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK;
BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083
[TBL] [Abstract][Full Text] [Related]
18. Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study.
Zhao JD; Liu J; Ren ZG; Gu K; Zhou ZH; Li WT; Chen Z; Xu ZY; Liu LM; Jiang GL
Radiat Oncol; 2010 Feb; 5():12. PubMed ID: 20149262
[TBL] [Abstract][Full Text] [Related]
19. 6-Methoxyethylamino-numonafide inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib.
Liu Y; Lou G; Norton JT; Wang C; Kandela I; Tang S; Shank NI; Gupta P; Huang M; Avram MJ; Green R; Mazar A; Appella D; Chen Z; Huang S
FASEB J; 2017 Dec; 31(12):5453-5465. PubMed ID: 28821631
[TBL] [Abstract][Full Text] [Related]
20. Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.
Tovar V; Cornella H; Moeini A; Vidal S; Hoshida Y; Sia D; Peix J; Cabellos L; Alsinet C; Torrecilla S; Martinez-Quetglas I; Lozano JJ; Desbois-Mouthon C; Solé M; Domingo-Domenech J; Villanueva A; Llovet JM
Gut; 2017 Mar; 66(3):530-540. PubMed ID: 26658144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
